Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult

JAAD Case Rep. 2024 Jun 15:52:34-37. doi: 10.1016/j.jdcr.2024.05.038. eCollection 2024 Oct.

Authors

Courtney M Kenyon¹, Brenna G Kelly², Anneli R Bowen², Matthew Gumbleton^{3

4}, Dekker C Deacon^{2

4}

Affiliations

¹ University of Utah Spencer Fox Eccles School of Medicine, Salt Lake City, Utah.
² Department of Dermatology, University of Utah, Salt Lake City, Utah.
³ Division of Oncology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
⁴ Huntsman Cancer Institute, Salt Lake City, Utah.

No abstract available

Keywords: COVID-19; immune checkpoint inhibitor; immune-related adverse event; immunotherapy; lichen striatus; rash; viral infection.

Publication types

Case Reports